ICIKINASE 1500000 IU Injection is a high-potency thrombolytic agent containing 1.5 million International Units of Streptokinase specifically formulated for rapid and effective dissolution of fibrin clots in acute cardiovascular emergencies. This injectable drug is primarily used in the hospital setting for treating acute myocardial infarction (AMI), pulmonary embolism (PE), deep vein thrombosis (DVT), arterial thrombosis or embolism, and to clear occluded arteriovenous cannulae. Streptokinase, the active component of ICIKINASE, activates plasminogen to plasmin, facilitating the breakdown of fibrin clots and restoring blood flow, thereby minimizing ischemic tissue damage and reducing mortality risk associated with thrombotic cardiovascular events. Administered via intravenous infusion over 60 minutes under strict medical supervision, ICIKINASE ensures effective thrombolysis with a standardized dosage of 1.5 million IU for AMI cases. Packaged with sterile diluent in a vial and requiring refrigeration at 2°C to 8°C, this injection is intended strictly for hospital use by trained healthcare professionals, ensuring patient safety and optimal therapeutic outcomes. Its use demands vigilant monitoring of bleeding risks, blood pressure, and ECG, especially in contraindicated cases like recent stroke or active bleeding. As a vital, life-saving cardiovascular medicine, ICIKINASE stands as an essential injectable thrombolytic agent in advanced clinical thrombolytic therapy.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Streptokinase 1.5 Million IU |
| Therapeutic Category | Thrombolytic Agent / Cardiovascular Medicine |
| Indications | Acute Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thromboembolism, Occluded Arteriovenous Cannulae |
| Dosage Form | Injectable solution for intravenous infusion |
| Standard Dosage | 1.5 million IU infused over 60 minutes |
| Mechanism of Action | Activates plasminogen to plasmin to dissolve fibrin clots |
| Packaging | Vial containing Streptokinase with sterile diluent |
| Storage Conditions | Refrigerate at 2°C – 8°C, protect from light, do not freeze |
| Administration Setting | Hospital / ICU use only by trained professionals |
| Safety Monitoring | Requires monitoring of blood pressure, ECG, and bleeding parameters |
| Attributes | Description |
|---|---|
| Product Type | Injection |
| Active Substance | Streptokinase |
| IU Strength | 1,500,000 IU |
| Therapeutic Use | Thrombolytic for clot dissolution |
| Route of Administration | Intravenous infusion |
| Indications Specificity | AMI, PE, DVT, Arterial Thrombosis, AV Cannulae occlusion |
| Dosage | 1.5 million IU over 60 minutes (standard for AMI) |
| Packaging Details | Single vial with sterile diluent |
| Storage | 2°C – 8°C, no freezing, shield from light |
| Contraindications | Active internal bleeding, recent stroke, severe hypertension, hemorrhagic disorders |
| Professional Use | Strict medical supervision in hospital settings |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ICIKINASE is administered via intravenous infusion over 60 minutes, with a standard dose of 1.5 million IU, under strict medical supervision in hospital or ICU settings.
Yes, it is contraindicated in patients with active internal bleeding, recent stroke, severe hypertension, or hemorrhagic disorders to avoid bleeding complications.
Store the vial refrigerated between 2°C and 8°C, protect from light exposure, and do not freeze to ensure the stability and potency of the medication.
Yes, ICIKINASE is indicated for dissolving clots in occluded arteriovenous cannulae, facilitating restoration of patency.
Continuous monitoring of blood pressure, electrocardiogram (ECG), and bleeding parameters is mandatory to manage therapeutic safety during thrombolysis.
Country Of Origin: India
Product Name: ICIKINASE 15,00,000 IU Injection
Generic Name: Streptokinase (1.5 Million IU)
Therapeutic Category: Thrombolytic Agent / Cardiovascular Medicine
Product Description:
ICIKINASE Injection contains Streptokinase, a thrombolytic (clot-dissolving) medicine used in the management of acute myocardial infarction (heart attack), pulmonary embolism, deep vein thrombosis, and arterial thromboembolism.
It works by activating plasminogen into plasmin, which breaks down fibrin clots and restores normal blood flow in blocked vessels.
Indications:
• Acute Myocardial Infarction (AMI)
• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Arterial Thrombosis or Embolism
• Occluded arteriovenous cannulae
Mechanism of Action:
• Streptokinase binds with plasminogen to form an activator complex.
• This converts plasminogen to plasmin, which dissolves fibrin clots.
• Helps restore blood circulation and prevent tissue damage.
Dosage & Administration:
• Administered by intravenous infusion only under hospital/ICU settings.
• Standard adult dose for AMI: 1.5 million IU infused over 60 minutes.
• Dosage may vary based on indication and patient condition.
(To be given by trained healthcare professionals only.)
Key Benefits:
• Rapid clot dissolution in life-threatening conditions.
• Reduces risk of mortality in acute heart attack patients.
• Restores blood flow and prevents tissue necrosis.
Packaging:
• Vial containing 15,00,000 IU Streptokinase with sterile diluent.
Storage:
• Store at 2°C – 8°C (Refrigerated).
• Protect from light.
• Do not freeze.
Important Notes:
• For hospital use under strict medical supervision only.
• Contraindicated in patients with active internal bleeding, recent stroke, severe hypertension, or history of hemorrhagic disorders.
• Close monitoring of blood pressure, ECG, and bleeding parameters is mandatory.
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
